Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage

Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage

Experimental & Translational Stroke Medicine, February 2016

26893821

Frieder Schlunk, Waltraud Pfeilschifter, Kazim Yigitkanli, Eng H. Lo, Christian Foerch

No evidence-based therapy is available for patients with acute intracerebral hemorrhage (ICH). In view of the profound inflammatory reaction in the perilesional tissue, we investigated in a well-characterized experimental model whether the administration of the immunomodulator fingolimod (FTY720) is neuroprotective in acute ICH. ICH was induced by means of a stereotactic intrastriatal injection of collagenase type VII-S. FTY720 (1 mg/kg) was administered intraperitoneally 1 h after ICH induction. Hematoma volume was assessed spectrophotometrically at 24 h after ICH induction. The following endpoints were determined at 24 and 72 h, respectively: mortality rate and neurologic outcomes, edema formation, and MMP-9 activity. Twenty-four hour after ICH induction, hematoma volume was not statistically different between groups. No difference was found in mortality and neurologic outcomes at 24 and 72 h between FTY720 treated mice and controls. Edema formation was present in both groups on the ipsilateral side with no statistical difference between groups at both time points. No difference was found in MMP-9 levels after 24 and 72 h between groups. Our results suggest that FTY720 has no beneficial effects in the acute phase of experimental ICH.